纳武利尤单抗在非小细胞肺癌治疗中的研究进展

肺癌是全球癌症死亡的主要原因之一。其中非小细胞肺癌(non-small cell lung cancer,NSCLC)占所有肺癌病例的85%以上,尽管化疗及靶向治疗改善了患者临床疗效,但预后仍欠佳。免疫治疗的发展改变了NSCLC患者的治疗策略。纳武利尤单抗是一种针对程序性死亡受体-1(programmed cell death-1,PD-1)的完全人源化的IgG4单克隆抗体,是首个被批准用于晚期NSCLC治疗的免疫检查点抑制剂。纳武利尤单抗已经成为晚期NSCLC治疗的主要药物,但临床上尚缺乏预测疗效的生物标志物。本文针对纳武利尤单抗的作用机制、药代动力学、单药治疗、联合治疗、不良反应和潜在生物标志物的最新进展进行综述。

Research progress on the treatment of non-small cell lung cancer with nivolumab

Lung cancer is the leading cause of cancer death and non-small cell lung cancer (NSCLC) accounts for >85% of all cancer deaths. Although chemotherapy and targeted therapy have improved clinical outcomes, prognosis remains poor. With the development of immunotherapy, the treatment strategy for patients with NSCLC has changed. Nivolumab, a human immunoglobulin G4 monoclonal antibody, was the first programmed cell death protein-1 (PD-1) inhibitor drug to be approved for treating advanced NSCLC and has become the primary drug for treating advanced NSCLC. However, there remains a lack of clinical biomarkers to predict the efficacy of nivolumab. In this review, we discuss the progress of therapeutic mechanisms, pharmacokinetics, pharmacology, clinical trials of monotherapy and combined therapy, adverse events, and predictive biomarkers.